AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact

Roche gave several presentations at AAIC 2026 on trontinemab’s potential role in Alzheimer’s as the drug progresses through Phase III trials. The pharma company gave several presentations at AAIC 2026 on trontinemab’s potential role in Alzheimer’s as the drug progresses through Phase III trials. Roche presented new data on its anti-amyloid therapy, trontinemab, while announcing it will initiate a trial on the drug focused on its potential in early Alzheimer’s. Credit: Atthapon Raksthaput / Shutterstock.com. Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines the potential of early treatment in boosting…

Source: Clinical Trials Arena